[icon of heart]

NEW CV INDICATION: REDUCE THE RISK OF MACE-3 FOR ADULTS WITH T2D WHO HAVE ESTABLISHED CVD OR MULTIPLE CV RISK FACTORS LEARN MORE.

[icon of heart]

NEW CV INDICATION: REDUCE THE RISK OF MACE-3 FOR ADULTS WITH T2D WHO HAVE ESTABLISHED CVD OR MULTIPLE CV RISK FACTORS LEARN MORE.

With the addition of the CV indication, Trulicity is proven to do more1

Trulicity is the only GLP-1 RA that provides these three benefits together

*In clinical studies, the range of A1C reduction from baseline was 0.7% to 1.6% for the 0.75 mg dose and 0.8% to 1.6% for the 1.5 mg dose.1,2 For more information on clinical trials, click here.

Recommended starting dose is 0.75 mg. Dose can be increased to 1.5 mg.

Trulicity 1.5 mg reduced the risk of MACE-3 (CV death, nonfatal MI, or nonfatal stroke) by 12% in patients without established CVD who have multiple CV risk factors and patients with established CVD.4

Primary prevention: Reducing the risk of atherosclerotic cardiovascular disease (ASCVD) by preventing or managing risk factors. Secondary prevention: Reducing the risk of another event in people who have had a serious CV incident or procedure5

§In a study, 99% of patients reported that overall, the Trulicity Pen was easy or very easy to use.3

GLP-1 RA=glucagon-like peptide-1 receptor agonist; MACE=major adverse cardiovascular events; CV=cardiovascular; MI=myocardial infarction; T2D=Type 2 Diabetes

Study description3

  • Phase 3b, multicenter,single-arm, outpatient study on the safe and effective use of the Trulicity single-dose pen in patients with type 2 diabetes who were naïve to self-injection and injecting others (n=214)
  • The primary objective of a success rate significantly greater than 80% at the fourth weekly injection was met. 99.1% [95% CI: 96.6% to 99.7%] (n=209) of patients successfully completed each step in the sequence of drug administration after proper self-injection training at baseline
  • Limitations include the administration of placebo rather than active drug product and the willingness of injection-naïve patients to self-inject, which may not be entirely representative of an injection-naïve type 2 diabetes patient population. The patients in this study with fairly well-controlled type 2 diabetes may not be entirely representative of an injection-naïve population progressing to injectable therapy. In clinical practice, patient training on self-injection with the single-dose pen may differ from the method in this study
  • After the final self-injection, patients completed a 12-item ease-of-use module (secondary endpoint). 208 (99%) out of 210 patients reported that overall, the single-dose pen was “easy” or “very easy” to use

Indication and Important Safety Information 
WARNING: POTENTIAL RISK OF THYROID TUMORS INCLUDING THYROID CANCER

Indication and Important Safety Information 
WARNING: POTENTIAL RISK OF THYROID TUMORS INCLUDING THYROID CANCER

Back to top